Abstract
Dasatinib is a small molecule tyrosine kinase inhibitor with multiple targets including kit, PDGFR, and SRC. This prospective study evaluated the efficacy and safety of dasatinib as third-line treatment for gastrointestinal stromal tumors (GIST). The study enrolled adult patients (≥18 years of age) with histologically confirmed unresectable and/or metastatic GIST whose disease progressed despite imatinib and sunitinib therapy. Dasatinib (50 mg twice daily) was given orally for 1 week and escalated to 70 mg twice daily orally. The primary endpoint was to the 3-month progression-free survival (PFS) rate. Blood samples were acquired before dasatinib therapy for examination of gene mutations by next-generation sequencing (NGS). From May 2016 to June 2018, 58 patients from 9 Chinese medical centers were enrolled in this study. The 3-month PFS rate was 53.4% and the median overall survival (OS) was 14.0 months. Neither primary nor secondary gene mutations predicted the efficacy of dasatinib. Wild-type GIST patients had longer PFS (5.5 months). The most common adverse events were anemia, proteinuria, fatigue, neutropenia, and diarrhea. The concordance of KIT/PDGFRA mutation was 61.9% between tissue and peripheral blood samples and add...Continue Reading
References
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jun 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher L CorlessMichael C Heinrich
Oct 19, 2006·Lancet·George D DemetriPaolo G Casali
Oct 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichGeorge D Demetri
Mar 25, 2010·BMJ : British Medical Journal·Kenneth F SchulzUNKNOWN CONSORT Group
Jan 14, 2011·Current Drug Targets·Antonio GnoniVito Lorusso
Jan 28, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Claudia MirandaMilo Frattini
Nov 28, 2012·Lancet·George D DemetriUNKNOWN GRID study investigators
Jan 9, 2013·Annals of Internal Medicine·An-Wen ChanDavid Moher
Jul 11, 2013·PloS One·Yuan-Shuo HsuehLi-Tzong Chen
Aug 8, 2013·British Journal of Cancer·J G van OosterwijkJ V M G Bovée
Sep 23, 2014·BMC Cancer·Margherita NanniniMaria A Pantaleo
May 11, 2017·Oncotarget·Chun-Nan YehJen-Shi Chen
Sep 20, 2017·Proceedings of the National Academy of Sciences of the United States of America·Benedikt BosbachPeter Besmer
Nov 3, 2017·Science Translational Medicine·Erica K EvansChristoph Lengauer
Nov 15, 2017·Molecular Cancer Therapeutics·Hao XuZekuan Xu
Jan 10, 2018·Cancer·Michael MontemurroSerge Leyvraz
Mar 1, 2018·Oncogenesis·Thomas C BeadnellRebecca E Schweppe
May 2, 2018·JAMA Oncology·Scott M SchuetzeLaurence H Baker
Jun 22, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoshikuni KawaguchiJean-Nicolas Vauthey
Jun 23, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Michael OffinHelena A Yu
Citations
Mar 3, 2021·Drugs & Aging·Monika Dudzisz-ŚledźPiotr Rutkowski
Mar 20, 2021·Nature Reviews. Disease Primers·Jean-Yves BlayMargaret von Mehren
Jun 14, 2021·International Journal of Biological Macromolecules·Zili SuoHui Li